drugset / Trial / NCT00664599
Rituximab for the Treatment of Severe Ocular Manifestations of Behcet's Disease
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this study is to find if Rituximab can improve severe ocular lesions of Behcet's Disease.
Timeline
- Start
- 2006-04
- Primary completion
- 2008-01
- Completion
- 2008-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Azathioprine | Small molecule | 3 mg/kg | — |
| Comparator | Cyclophosphamide | Other / unclassified | 1000 mg | Other |
| Subject | Rituximab | Monoclonal antibody | 1500 mg | Other |
| Background | Methotrexate | Small molecule | 15 mg | — |
| Background | Prednisolone | Other / unclassified | 0.5 mg | — |
| Background | Prednisolone | Other / unclassified | 0.5 mg/kg | — |